Evidence map›Paper›PMID 28668565›Full record

ArticleVaccine2017

M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.

Yasuko Hatta, David Boltz, Sally Sarawar, Yoshihiro Kawaoka, Gabriele Neumann, Pamuk Bilsel

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. The Quest for a Truly Universal Influenza Vaccine.Frontiers in cellular and infection microbiology · 2019
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Yasuko HattaFluGen Inc., Madison, WI 53711, USA.
David BoltzIIT Research Institute, Chicago, IL 60616, USA.
Sally SarawarThe Biomedical Research Institute of Southern California, Oceanside, CA 92056, USA.
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53711, USA; Division of Virology, Department of Microbiology and Immunology, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; Division of Virology, Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Gabriele NeumannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53711, USA.
Pamuk BilselFluGen Inc., Madison, WI 53711, USA. Electronic address: pbilsel@flugen.com.
FluGen (United States) · USUniversity of Wisconsin–Madison · USBiomedical Research Institute of Southern California · USIIT Research Institute · US

Funding

A Novel Live Non-replicating Universal Vaccine for InfluenzaR01AI111451 · NIAID · BIOMEDICAL RESEARCH INSTIT/ SOUTHERN, CA · PI SARAWAR, SALLY R. · 2014 to 2018
$4.4M
Development of a novel highly effective influenza vaccineR44AI109925 · NIAID · FLUGEN, INC. · PI BILSEL, PAMUK, SARAWAR, SALLY R. · 2018 to 2019
$1.5M
Development of a novel highly effective influenza vaccineR41AI109925 · NIAID · FLUGEN, INC. · PI BILSEL, PAMUK, SARAWAR, SALLY R. · 2014 to 2015
$600k
NIAID NIH HHS R01 AI111451NIAID NIH HHS R41 AI109925NIAID NIH HHS R44 AI109925
6 · The paper itself

Abstract

The emergence of highly pathogenic avian influenza H5N1 viruses has heightened global concern about the threat posed by pandemic influenza. To address the need for a highly effective universal influenza vaccine, we developed a novel M2-deficient single replication (M2SR) influenza vaccine virus and previously reported that it provided strong heterosubtypic protection against seasonal influenza viruses in mice. In the current study, we assessed M2SR induced protection against H5N1 influenza in mice and ferrets. Mice were intranasally inoculated with M2SR viruses containing the HA and NA from A/Vietnam/1203/2004 (M2SR H5N1) or A/California/07/2009 (M2SR H1N1). All M2SR vaccinated mice survived lethal challenge with influenza A/Vietnam/1203/2004 (H5N1), whereas 40% of mice vaccinated with recombinant H5 HA and none of the naïve controls survived. M2SR H5N1 provided sterile immunity, whereas low levels of virus were detected in the lungs of some M2SR H1N1 vaccinated mice. In contrast, recombinant H5 HA vaccinated mice and naïve controls showed systemic infection. M2SR H5N1 induced strong serum and mucosal antibody responses (IgG and IgA classes) against H5 HA, with high hemagglutination inhibition (HAI) titers. In contrast, while M2SR H1N1 elicited cross-reactive antibodies recognizing the H5 HA2 stalk region or the neuraminidase, no HAI activity against H5N1 virus was detected after M2SR H1N1 immunization. Both M2SR H5N1 and H1N1 also protected ferrets against lethal challenge with A/Vietnam/1203/2004. A prime-boost regimen provided optimal protection with no virus detected in the respiratory tract or brain after challenge. As in the mouse model, only the M2SR H5N1 vaccine induced HAI antibodies against the challenge virus in ferrets, while the M2SR H1N1 was able to provide protection without the induction of HAI antibodies. In summary, effective protection against highly pathogenic H5N1 influenza virus was provided by both homologous H5N1 M2SR and heterologous H1N1 M2SR demonstrating the cross-protective attributes of the M2SR platform.

Indexed as

Administration, IntranasalAnimalsAntibody FormationDisease Models, AnimalFemaleFerretsImmunity, MucosalInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza VaccinesLungMaleMice, Inbred BALB COrthomyxoviridae InfectionsSurvival AnalysisTreatment OutcomeInfluenza VaccinesVaccines, AttenuatedHA2 stalk regionHemagglutination inhibitionHeterosubtypic immunityHighly pathogenic H5N1 avian influenzaLong-lasting protectionM2-deficientNeuraminidaseSingle replicationSterilizing immunityUniversal influenza vaccine

Identifiers

PMID28668565
PMCPMC5587242
OpenAlexW2731678993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.